Janet L Nichol
Overview
Explore the profile of Janet L Nichol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nugent D, McMillan R, Nichol J, Slichter S
Br J Haematol
. 2009 May;
146(6):585-96.
PMID: 19466980
Chronic immune thrombocytopenia (ITP) is a haematological disorder in which patients predominantly develop skin and mucosal bleeding. Early studies suggested ITP was primarily due to immune-mediated peripheral platelet destruction. However,...
2.
Bussel J, Kuter D, Pullarkat V, Lyons R, Guo M, Nichol J
Blood
. 2008 Nov;
113(10):2161-71.
PMID: 18981291
Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and mucocutaneous bleeding. In previous studies romiplostim (AMG531), a thrombopoiesis-stimulating protein, increased platelet counts in most patients with chronic...
3.
Mathias S, Gao S, Miller K, Cella D, Snyder C, Turner R, et al.
Health Qual Life Outcomes
. 2008 Feb;
6:13.
PMID: 18261217
Background: Immune thrombocytopenic purpura (ITP), a condition characterized by autoimmune-mediated platelet destruction and suboptimal platelet production, is associated with symptoms such as bruising, epistaxis, menorrhagia, mucosal bleeding from the gastrointestinal...
4.
Kuter D, Bussel J, Lyons R, Pullarkat V, Gernsheimer T, Senecal F, et al.
Lancet
. 2008 Feb;
371(9610):395-403.
PMID: 18242413
Background: Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts...
5.
Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, et al.
J Clin Pharmacol
. 2007 Oct;
47(12):1489-97.
PMID: 17925591
AMG 531 is a novel thrombopoiesis-stimulating peptibody being investigated for the treatment of chronic immune thrombocytopenic purpura. This double-blind, phase I study evaluated the safety, pharmacodynamics, and pharmacokinetics of AMG...
6.
McMillan R, Bussel J, George J, Lalla D, Nichol J
Am J Hematol
. 2007 Aug;
83(2):150-4.
PMID: 17722072
Adult chronic immune thrombocytopenic purpura (ITP) is a disorder manifested by varying degrees of purpura and mucosal bleeding, rarely including intracranial hemorrhage. Therapy is aimed at increasing the patient's platelet...
7.
Mathias S, Bussel J, George J, McMillan R, Okano G, Nichol J
Clin Ther
. 2007 Aug;
29(5):950-962.
PMID: 17697914
Background: The Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ) was developed to assess disease-specific quality of life (QoL) in adults with ITP. It is a 44-item questionnaire that includes scales...
8.
Mathias S, Bussel J, George J, McMillan R, Okano G, Nichol J
Health Qual Life Outcomes
. 2007 Feb;
5:11.
PMID: 17316442
Background: No validated disease-specific measures are available to assess health-related quality of life (HRQoL) in adult subjects with immune thrombocytopenic purpura (ITP). Therefore, we sought to develop and validate the...
9.
Newland A, Caulier M, Kappers-Klunne M, Schipperus M, Lefrere F, Zwaginga J, et al.
Br J Haematol
. 2006 Oct;
135(4):547-53.
PMID: 17061981
Abstract The objective of this open label, phase 1-2, multicentre trial was to evaluate the safety of AMG 531, a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in...
10.
Bussel J, Kuter D, George J, McMillan R, Aledort L, Conklin G, et al.
N Engl J Med
. 2006 Oct;
355(16):1672-81.
PMID: 17050891
Background: Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with...